Most benefits appear in patients with insulin resistance or prediabetes, where normalizing glucose dynamics has secondary weight-management effects
Its worth noting that Semaglutide GLP-1 is typically not recommended to those who are younger than 18 years old, those who have specific medical issues, or pregnant or breastfeeding women due to limited research on its effects
These were initially identified by high affinity binding of 125 I-GLP or 125 I-[Y 39 ]exendin-4 to beta cell lines, gastric chief and parietal cells and pancreatic acinar cells (39, 88, 94, 104)
Fact: Stopping GLP-1 medications suddenly may contribute to increased appetite and rapid weight regain, so its important to work with a healthcare provider on a transition plan
PubMed: 35267907 Chilibeck PD, et al
1) S-850S-851 (2012)